Share This Page
Drug Price Trends for NDC 00078-1007
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-1007
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KESIMPTA 20 MG/0.4 ML PEN | 00078-1007-68 | 22647.51857 | ML | 2025-12-17 |
| KESIMPTA 20 MG/0.4 ML PEN | 00078-1007-68 | 22625.88897 | ML | 2025-11-19 |
| KESIMPTA 20 MG/0.4 ML PEN | 00078-1007-68 | 22616.03984 | ML | 2025-10-22 |
| KESIMPTA 20 MG/0.4 ML PEN | 00078-1007-68 | 22578.60323 | ML | 2025-09-17 |
| KESIMPTA 20 MG/0.4 ML PEN | 00078-1007-68 | 22600.40769 | ML | 2025-08-20 |
| KESIMPTA 20 MG/0.4 ML PEN | 00078-1007-68 | 22619.00139 | ML | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-1007
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00078-1007
Introduction
The National Drug Code (NDC) 00078-1007 pertains to a specific pharmaceutical product within the U.S. market, serving as critical data for stakeholders involved in manufacturing, distribution, regulatory oversight, and investment strategies. Accurate market analysis and price projection for this drug hinge on several factors including clinical demand, competitive landscape, regulatory status, and broader industry trends.
This report delivers a comprehensive analysis of the current market environment and forecasts future price trajectories for NDC 00078-1007, enabling informed decision-making for pharmaceutical companies, investors, and healthcare providers.
Drug Profile and Regulatory Context
While specific details about NDC 00078-1007 are proprietary and deriving precisely from FDA records or industry databases, typical NDC entries indicate the drug’s formulation, manufacturer, and package size. Based on available data, this NDC likely corresponds to a widely prescribed therapeutic—possibly a biologic or specialty medication—placing it within a high-demand, high-value segment with complex market dynamics.
Given the regulatory environment, drugs approved over the past decade have faced evolving pricing scrutiny, especially amid increasing pressures towards affordability and transparency. Any pricing outlook must account for FDA regulatory status, patent protections, and potential biosimilar or generic entry as regulatory pathways influence market competition.
Market Dynamics
1. Therapeutic Area and Patient Demographics
The relevant therapeutic class for NDC 00078-1007 significantly influences its market trajectory. For instance, biologic therapies indicates a substantial initial market exclusivity and high acquisition costs, while small-molecule drugs typically face earlier patent expiry and generic competition.
The patient demographics—age, prevalence of the condition, and regional healthcare access—shape demand fluctuations. For chronic or severe diseases, consistent utilization propels stable revenue streams, whereas market saturation might pressure prices over time.
2. Competitive Landscape
Market competitiveness hinges on existing and emerging rivals, including biosimilars, generics, and alternative therapies. Biosimilar entry, particularly in biologics, tends to exert downward pressure on drug prices, accelerating the decline in average selling prices (ASPs) post-patent expiry.
The extent of patent protection and exclusivity periods directly influence production and pricing strategies. If NDC 00078-1007 benefits from patent protection and limited biosimilar competition, upward or stable pricing is likely in the near term.
3. Regulatory and Policy Factors
In recent years, regulatory agencies have applied increased scrutiny to drug pricing, leading to policy proposals such as price caps, value-based pricing, and increased transparency. These policies can delay launch of biosimilars, influence reimbursement strategies, and impose price ceilings.
Additionally, patient access programs, rebates, and formulary inclusion by insurers heavily influence net prices and market share.
4. Manufacturing and Supply Chain
Supply chain robustness impacts pricing stability. Disruptions, such as those caused by global events or raw material shortages, can lead to supply constraints, driving prices upward temporarily. Conversely, manufacturing efficiencies or shift to biosimilar production can reduce costs over time.
Historical Price Trends
Historically, innovator biologics or specialty drugs aligned with NDC 00078-1007 have experienced high launch prices, often between US$5,000 to US$50,000 per treatment course, depending on the therapeutic area and treatment regimen[1]. Over subsequent years, prices tend to decline due to biosimilar competition, patent expiries, or utilization management strategies.
For example, biologics such as Humira (adalimumab) initially launched at over US$20,000 annually, saw significant price erosion post-biosimilar approval, resulting in reductions of 20-30% or more[2]. Such trends suggest NDC 00078-1007’s price trajectory will follow similar patterns contingent on competitive dynamics and regulatory milestones.
Price Projection Analysis
Near-Term (1-3 Years)
If NDC 00078-1007 currently enjoys patent exclusivity and limited biosimilar competition, prices are expected to remain relatively stable or experience modest increases driven by inflationary adjustments and enhanced formulation indications.
However, impending patent expiry or regulatory hurdles for biosimilar approval could initiate early price erosion. Price stability in this period is also dependent on payer negotiations, rebate structures, and market access strategies.
Medium-Term (3-7 Years)
Assuming biosimilar entry, a significant decline (potentially 30-50%) in list prices can be anticipated, supported by global biosimilar adoption. The competitive landscape will drive manufacturers to innovate or expand indications to sustain revenue.
Pricing models project a gradual decline, with net prices influenced by rebate and reimbursement frameworks. Market access policies emphasizing value-based care could further compress prices, emphasizing the importance of real-world impact and clinical value in maintaining margins.
Long-Term (7+ Years)
Post-expiration, the dominant driver becomes biosimilar competition and manufacturing costs. Generic or biosimilar penetration may bring prices down by over 50% compared to peak innovator prices, aligning with historical data from biologic markets.
Market saturation, combined with policy-driven pricing constraints, will further shape long-term prices, emphasizing the importance of lifecycle management strategies such as new indications, combination therapy, or patient support programs.
Price Optimization Strategies
Pharmaceutical manufacturers can leverage multiple approaches to optimize prices for NDC 00078-1007:
- Value-Based Pricing: Align prices with demonstrated clinical outcomes.
- Market Segmentation: Tailor pricing based on payer types, geographic regions, or patient subgroups.
- Rebate and Contracting Negotiations: Enhance net prices through strategic partnerships with payers.
- Lifecycle Management: Extend patent protections via new formulations or indications.
Future Market Opportunities
The increasing adoption of biosimilars and development of next-generation therapies represent both risks and opportunities. Companies capable of early biosimilar entry and competitive pricing might gain dominant market share, while innovator manufacturers must focus on differentiating clinical benefits to sustain value.
Emerging areas, including personalized medicine and combination therapies, could diversify revenue streams, mitigate price erosion, and open new markets.
Key Takeaways
- The current market for NDC 00078-1007 is characterized by high initial prices supported by patent exclusivity, with significant susceptibility to biosimilar competition in the coming years.
- Price stabilization is expected in the short term, with medium to long-term declines aligning with biosimilar proliferation and policy-driven price controls.
- Manufacturers should focus on lifecycle management, value-based pricing, and market access optimization to maximize revenue.
- Anticipate a substantial price reduction (up to 50%) post-biosimilar entry, influencing long-term revenue forecasts.
- Strategic positioning regarding regulatory developments, patent timelines, and market differentiation is crucial for maintaining profitability.
FAQs
1. When is the likely patent expiry for NDC 00078-1007?
Patent expiry depends on the specific formulation and filing dates. Typically, biologics filed before 2010 enjoy patent protection for approximately 12-14 years, often translating to clinical exclusivity through the early to mid-2030s. Precise valuation requires review of the drug’s patent and data exclusivity status.
2. How significant is biosimilar competition for this drug?
Biosimilar competition is a key factor shaping the future price trajectory. If biosimilars for NDC 00078-1007 are approved and commercially launched within the next 3-5 years, expect notable price erosion. The extent depends on regulatory pathways, patent litigation outcomes, and market acceptance.
3. What are the main factors influencing net prices for this drug?
Rebate agreements, formulary positioning, payer negotiations, and patient assistance programs are primary determinants of net prices beyond the list price. Policy measures like Medicare and private payer price controls further influence net revenue.
4. How can manufacturers extend the lifecycle of NDC 00078-1007?
Strategies include developing new indications, formulation enhancements, combination therapies, or biosimilar product lines. Engaging in post-marketing studies to demonstrate superior efficacy or safety can also justify premium pricing.
5. What impact will healthcare policy trends have on future pricing?
Policy efforts toward drug affordability, transparency, and value-based reimbursement are likely to exert downward pressure on prices, especially for high-cost biologics. Manufacturers need to align product value propositions with evolving regulatory standards to sustain profitability.
References
[1] IMS Institute for Healthcare Informatics. The Global Use of Medicines: Outlook to 2020. 2015.
[2] Kantar Health. Biologic Price Trends Post-Biosimilar Entry. 2021.
More… ↓
